Back to list

Welcome back, Medscape Readers! This month in Dermatology, faculty of the Inaugural PDE Symposium come together and share the most critical practice pearls they presented to attendees, and also the critical pearls they themselves learned and plan to take back to their practices. This new meeting was the first of its kind and was a huge success. We hope to build on this for next year and will make sure to put it on your radar for scheduling CME in 2024.

Last month we spoke with Dr. Pearl E. Grimes, Symposium Chair and Dr. Jill S. Waibel, Course Director of the PDE Symposium, who shared sneak peek clinical pearls from their presentations. Click here if you missed it. 

Save the Date and Register Now!

2023 Skin of Color Update  

October 6–8, 2023 | New York Hilton Midtown | New York, NY

  • Educate dermatology clinicians and trainees to best ​diagnose and treat dermatologic disorders in populations with skin of color, including those that disproportionately affect higher skin phototypes. 
  • Educate clinicians and trainees to best treat the aesthetic needs of patients with skin of color.
  • Provide the latest updates on diagnostic, therapeutic, and cosmetic treatment best practices for dermatologic conditions in populations with skin of color.
  • Equip practitioners to deliver safe, effective, and culturally competent care to a diverse patient population.
  • Click here to register!

46th Annual Hawaii Derm 2024 

  • Presidents’ Week February 19, 2024 
  • In-person event!
  • World-class faculty bring the latest dermatological advancements with presentations that go beyond the podium.
  • New developments in aesthetic medicine to the latest breakthroughs in the treatment of skin diseases.
  • Acne to atopic dermatitis, psoriasis to skin cancers, surgical pearls to nonsurgical facial rejuvenation, and more.

Keep current on new publications with our Derm Resource section below, with articles from JAMA Dermatology, Dermatology News, Cutis, NEJM and more. Thank you to Dr. Grimes and Dr. Waibel for assembly of such a highly anticipated event and for their time and expertise. Happy Spring and happy reading! —Colleen Hutchinson

Post-PDE Rundown: The Scoop on Last Month’s Inaugural PDE

Participant bios and affiliations can be found by clicking here. 

What was something you shared at PDE that was well received and practical for attendees to take back to practice and utilize?

Dr. Woolery-Lloyd: I spoke about the dermatologic diseases characterized by dermal hyperpigmentation, and I spoke about therapeutic options for these conditions. Many different treatment options have been reported to be helpful for dermal hyperpigmentation and I reviewed the research to support the use of these therapeutic options.

Dr. Taylor: To the patient with pigmentary disorders, recommend the application of a broad-spectrum SPF 30 or higher tinted sunscreen.

Dr. Siperstein: Hyperpigmentation in darker skin types can be treated safely with microneedling RF as long as insulated needles are utilized.

Dr. Elbuluk: Updates in vitiligo treatments and important considerations in management.

Dr. Kauvar: Pre-treatment with hydroquinone and corticosteroids for two to three weeks reduces the risk of post-inflammatory hyperpigmentation in high-risk individuals who undergo high energy laser or device-based procedures.

Dr. Pandya: The two most important pillars of therapy for vitiligo are 1) Stop the immune mediated attack on the skin by T cells and 2) stimulate melanocyte proliferation to repigment the skin. 

Dr. Berson: I received feedback that the attendees appreciated learning the mechanisms of action of the various ingredients used in topical cosmeceutical products for pigmentation. I was told the review was comprehensive and they felt it was helpful for them but also for explaining to patients.

What was something you LEARNED from other faculty that was practical for you to take back to practice and utilize?

Dr. Woolery-Lloyd: I learned about new treatment options for challenging disorders of hyperpigmentation. The lectures were extremely practical and applicable to my practice.

Dr. Taylor: The value of laser therapy for post-inflammatory hyperpigmentation.

Dr. Kauvar: The benefit of combining antioxidants and supplements with medical therapy for active and stable vitiligo.

Dr. Elbuluk: Various combination treatment approaches for challenging pigmentary disorders.

Dr. Pandya: Dr. Grimes reported that the lighter a person’s skin, the earlier the onset of melasma, indicating that melasma is a disorder caused by photo damage.

Dr. Siperstein:  I learned about nano laser technology!

Dr. Berson: I learned more about the JAK inhibitors, the use of various lasers and of oral TXA for treating patients with both vitiligo and hyperpigmentation.

Do you think the PDE meeting was a success and is a needed target symposium?

Dr. Pandya: Yes, I believe it was a success, judging from the many questions from the audience about the approach to managing vitiligo, melasma and other pigmentary disorders. For future meetings, I think we should have different experts present their evidence-based algorithms with clinical pearls for managing each disorder.

Dr. Elbuluk: Absolutely, it was an excellent meeting with outstanding faculty and high yield lectures.

Dr. Woolery-Lloyd: This meeting was a huge success. There was so much to learn. It offered very practical and relevant content that could be applied to my dermatology practice.  

Dr. Kauvar: The inaugural PDE symposium provided a forum for high level didactic sessions and exchange of ideas by clinicians and researchers devoted to improving the treatment of pigmentary disorders.  The PDES was a tremendous success and enabled the kind of cross pollination of ideas that help advance our care and treatment of patients.

Dr. Taylor: Definitely yes as no symposium targets pigmentary disorders. 

Dr. Siperstein: Yes, it is a very helpful course for dermatologists.

Dr. Berson: Truly a success! Everyone gave great feedback and this meeting is truly a great targeted symposium, covering all aspects of pigmentation and all skin types.

Dermatology Resource Section: 

Cutis From the Journals: Brepocitinib shows promise for psoriatic arthritis patients


JAMA Dermatology Editorial: Public Health and Diagnostic Approaches to Risk Stratification for Melanoma


NEJM Original Article: Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis


Medscape Skin of Color Update: October 6-8, 2023, New York, NY


Medscape February 46th Annual Hawaiian Dermatology Seminar; President’s Week 2024 


Cutis Original Research: Disparities in Melanoma Demographics, Tumor Stage, and Metastases in Hispanic and Latino Patients: A Retrospective Study